<div id="readability-page-1"><div><p><span></span></p><ul><li><span>AstraZeneca to report late-stage Datroway + Imfinzi lung cancer trial results later this year; continues Datroway studies in earlier-stage breast cancer and highlights patient-selection focus.</span> <span>1</span></li><li><span>AstraZeneca (AZN) moved its primary listing to the New York Stock Exchange in February. Shares now trade on the NYSE; this was the largest market-capitalization listing transfer in NYSE history.</span> <span>2</span></li></ul></div></div>

<p>AstraZeneca to report late-stage Datroway + Imfinzi lung cancer trial results later this year; continues Datroway studies in earlier-stage breast cancer and highlights patient-selection focus. 1AstraZeneca (AZN) moved its primary listing to the New York Stock Exchange in February. Shares now trade on the NYSE; this was the largest market-capitalization listing transfer in NYSE history. 2</p>

Key facts: AstraZeneca to report Datroway+Imfinzi results; NYSE move